HumAb1 conjugated to DM4 maytansinoid derivative showed anti-tumor efficacy in pre-clinical studies when administered to mice bearing cell surface LAMP1 positive patient-derived tumors [7, 8]. Here, LAMP1 is linked to neoplasm.